United Kingdom

People: Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

16 Aug 2019
Change (% chg)

$0.83 (+3.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Deschatelets, Pascal 

Dr. Pascal Deschatelets Ph.D. serves as Co-Founder, Chief Operating Officer of the Company. Dr. Deschatelets co-founder of our company and has served as our Chief Operating Officer since our inception in 2009. Dr. Deschatelets also co-founded Potentia and served as its Chief Operating Officer from 2001 to September 2016 and is a cofounder of Revon. Dr. Deschatelets received his Ph.D. in organic chemistry from the University of Montreal and his post-doctoral training in the laboratory of Dr. George Whitesides at Harvard University.

Basic Compensation

Total Annual Compensation, USD 625,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,237,360
Fiscal Year Total, USD 1,862,360

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --